Actinium Pharmaceuticals Inc (ATNM)

$1.61 -0.02 (-1.23%)
Market Cap 50.85M
Revenue (ttm) 0.00
Net Income (ttm) -38.24M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 151,200
Avg Vol 344,770
Day's Range N/A - N/A
Shares Out 31.20M
Stochastic %K 20%
Beta -0.32
Analysts Strong Sell
Price Target $5.00

Company Profile

Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. The company advances two clinical stage product candidates, Actimab-A, to treat patients with myeloid malignancies including acute myeloid leukemia and myelodysplastic syndromes; and Iomab-ACT, to improve patient access to and outcomes with cellular therapies, such as CAR-T for various blood cancer indications...

Industry: Biotechnology
Sector: Healthcare
Phone: 646 677 3870
Address:
100 Park Avenue, 23rd Floor, New York, United States
gooddoggie
gooddoggie Aug. 1 at 6:38 PM
$ATNM Ask Ann, August 1, 2025 Dear Ann, when I have severed heads they get so hot out in the sun. What can I do? -Muffy from Memphis Dear Muffy, I usually keep umbrellas just for that purpose. Also you might try severing the heads in cooler months. -Ann
0 · Reply
Raxothus
Raxothus Aug. 1 at 5:31 PM
EOD FOLLOW-UP - 08/01/25 Tracking continuation watch from 07/31 based on today’s highs vs prior close ✅ $AVTX – Closed 7.89, hit 8.75 (+10.9%). Strong open pop, but failed to hold VWAP or push further. ✅ $FRGE – Closed 21.90, hit 23.37 (+6.7%). Strong breakout at open, clean continuation. ❌ $ATNM – Closed 1.66, hit 1.68 (+1.2%). Weak range, lacked momentum. ❌ $ENGN – Closed 3.77, hit 3.86 (+2.4%). Modest move, but reclaimed VWAP and showed decent structure. ❌ $CCRD – Closed 29.00, hit 28.17 (–2.9%). Gapped down and faded. No continuation. 📊 Recap Total: 5 Winners: 2 Faders: 3 Accuracy: 40% ⚠️ $FRGE gave a clean continuation. $AVTX technically hit +10%, but failed to hold structure or VWAP. $ATNM, $ENGN and $CCRD failed to deliver range or setup. #VWAP #Continuation #SmallCaps #DayTrading #EODSetups #Accountability
0 · Reply
johnny4cures
johnny4cures Aug. 1 at 5:20 PM
$ATNM new data I believe
0 · Reply
gooddoggie
gooddoggie Aug. 1 at 4:49 PM
$ATNM Why I hate Mondays.
1 · Reply
gooddoggie
gooddoggie Aug. 1 at 10:12 AM
$ATNM UhOh. Now we’ve done it.
1 · Reply
johnny4cures
johnny4cures Aug. 1 at 3:59 AM
$ATNM an old publication but goodie
0 · Reply
johnny4cures
johnny4cures Aug. 1 at 3:41 AM
$ATNM If it is so obvious, the therapy works better than soc, fast track breakthroughs will speed up in the future, breakneck speed on approvals with ai, right.
1 · Reply
Raxothus
Raxothus Jul. 31 at 7:30 PM
EOD CONTINUATION WATCHLIST – 07/31/25 Focused on stocks that held VWAP and pushed into Power Hour with strength. $AVTX – 19.07% move, 4.7x volume, 9.1% VWAP stretch. Micro float. Strong move and held well above VWAP into close. Needs open over 7.96+ for continuation $FRGE – 26.4% move, 3.0x volume, 6.9% VWAP stretch. Micro float. Explosive action with strong close. Watching for gap and clean open over 21.8+ to extend $ATNM – 7.01% move, 2.0x volume, 3.0% VWAP stretch. Small float. Grinded up steadily with VWAP support. Needs push over 1.74 to stay in play $ENGN – 5.71% move, 6.2x volume, -0.5% VWAP stretch. Small float. Volume was strong, but faded late. Needs VWAP reclaim over 3.80+ to reset momentum $CCRD – 10.55% move, 6.1x volume, -0.5% VWAP stretch. Micro float. Volume surged but no late power. Needs strong gap and reclaim over 29.76+ to watch Watching for gap and VWAP continuation only. Catalyst + volume = edge. No random holds. #EOD #VWAP #Momentum #SmallCaps #DayTrading #ContinuationSetups
0 · Reply
noggindog
noggindog Jul. 31 at 5:05 PM
$ATNM Up 1% today AND volume above normal. Could this be a start to going above $2?
0 · Reply
johnny4cures
johnny4cures Jul. 31 at 4:45 PM
$ATNM How about some contrast and color on the potential for ATNM-400. Sales between the makers of keytuda and opdivo ~40 billion x 3 years from now is =120 billion with LOE on the horizon. Sales between pluvicto and Xtandi ~7 billion × 3 years =21 billion. Can they afford not to buy Actinium is a good question?
1 · Reply
Latest News on ATNM
Actinium Presents Data Supporting Paradigm Changing Potential of ATNM-400 in Prostate Cancer Demonstrating Its Superior Efficacy and Improved Survival in Treatment Resistant Tumor Models versus Pluvicto and ARPI Therapy, and Also Enhanced Efficacy in Combination with ARPI Therapy at the 4th Annual Targeted Radiopharmaceuticals Summit

Jul 31, 2025, 8:30 AM EDT - 1 day ago

Actinium Presents Data Supporting Paradigm Changing Potential of ATNM-400 in Prostate Cancer Demonstrating Its Superior Efficacy and Improved Survival in Treatment Resistant Tumor Models versus Pluvicto and ARPI Therapy, and Also Enhanced Efficacy in Combination with ARPI Therapy at the 4th Annual Targeted Radiopharmaceuticals Summit

Actinium Highlights Expanded Data Set for ATNM-400 in Prostate Cancer Demonstrating Superior Efficacy to Enzalutamide and Ability to Overcome Resistance to ARPI Therapy and PSMA-Ac-225/Lu-177 Labelled Radiotherapy at the Society of Nuclear Medicine & Molecular Imaging Annual Meeting

Jun 23, 2025, 11:30 AM EDT - 5 weeks ago

Actinium Highlights Expanded Data Set for ATNM-400 in Prostate Cancer Demonstrating Superior Efficacy to Enzalutamide and Ability to Overcome Resistance to ARPI Therapy and PSMA-Ac-225/Lu-177 Labelled Radiotherapy at the Society of Nuclear Medicine & Molecular Imaging Annual Meeting

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 27, 2025 in Actinium Lawsuit - ATNM

May 22, 2025, 5:45 AM EDT - 2 months ago

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 27, 2025 in Actinium Lawsuit - ATNM

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 27, 2025 in Actinium Lawsuit – ATNM

May 15, 2025, 1:43 PM EDT - 2 months ago

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 27, 2025 in Actinium Lawsuit – ATNM

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Actinium

May 14, 2025, 1:26 PM EDT - 2 months ago

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Actinium

Actinium Announces Enrollment of First Patient in the Iomab-ACT Commercial CAR-T Trial at the University of Texas Southwestern Medical Center

May 6, 2025, 8:45 AM EDT - 3 months ago

Actinium Announces Enrollment of First Patient in the Iomab-ACT Commercial CAR-T Trial at the University of Texas Southwestern Medical Center

Lawsuit for Investors in shares of Actinium Pharmaceuticals, Inc. (NYSE: ATNM) announced by the Shareholders Foundation

Apr 30, 2025, 7:25 AM EDT - 3 months ago

Lawsuit for Investors in shares of Actinium Pharmaceuticals, Inc. (NYSE: ATNM) announced by the Shareholders Foundation

Actinium Presents Data Showing ATNM-400 is More Efficacious than Pluvicto and is Highly Efficacious after Pluvicto Resistance in Prostate Cancer Tumor Models at the American Association for Cancer Research Annual Meeting

Apr 28, 2025, 8:30 AM EDT - 3 months ago

Actinium Presents Data Showing ATNM-400 is More Efficacious than Pluvicto and is Highly Efficacious after Pluvicto Resistance in Prostate Cancer Tumor Models at the American Association for Cancer Research Annual Meeting

Actinium Highlights Mutation Agnostic Antileukemic Activity of Actimab-A Against FLT3, NPM1, KMT2A and TP53 Mutations in AML Models Demonstrating Backbone Potential for Acute Myeloid Leukemia Treatment at the American Association for Cancer Research Annual Meeting

Apr 28, 2025, 8:00 AM EDT - 3 months ago

Actinium Highlights Mutation Agnostic Antileukemic Activity of Actimab-A Against FLT3, NPM1, KMT2A and TP53 Mutations in AML Models Demonstrating Backbone Potential for Acute Myeloid Leukemia Treatment at the American Association for Cancer Research Annual Meeting

ITM and Alpha-9 Oncology Enter Into Supply Agreement for Therapeutic Medical Radioisotope Actinium-225

Apr 24, 2025, 5:00 AM EDT - 3 months ago

ITM and Alpha-9 Oncology Enter Into Supply Agreement for Therapeutic Medical Radioisotope Actinium-225

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Actinium

Apr 19, 2025, 8:20 AM EDT - 3 months ago

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Actinium

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 27, 2025 in Actinium Pharmaceuticals, Inc. Lawsuit - ATNM

Apr 17, 2025, 5:45 AM EDT - 3 months ago

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 27, 2025 in Actinium Pharmaceuticals, Inc. Lawsuit - ATNM

Ibotta, Inc. Investors: Company Investigated by the Portnoy Law Firm

Apr 16, 2025, 10:01 AM EDT - 3 months ago

Ibotta, Inc. Investors: Company Investigated by the Portnoy Law Firm

IBTA

Gainey McKenna & Egleston Announces a Class Action Lawsuit Has Been Filed Against Actinium Pharmaceuticals, Inc. (ATNM)

Mar 28, 2025, 11:57 AM EDT - 4 months ago

Gainey McKenna & Egleston Announces a Class Action Lawsuit Has Been Filed Against Actinium Pharmaceuticals, Inc. (ATNM)

Actinium Pharmaceuticals Announces ATNM-400 a Novel Non-PSMA Targeting First in Class Prostate Cancer Radiotherapy Leveraging Actinium-225

Mar 27, 2025, 8:45 AM EDT - 4 months ago

Actinium Pharmaceuticals Announces ATNM-400 a Novel Non-PSMA Targeting First in Class Prostate Cancer Radiotherapy Leveraging Actinium-225

Actinium Pharmaceuticals to Host KOL Investor Call at 8am ET Today to Highlight Revamped Clinical Programs and Expanded Market Opportunities Including Newly Initiated Actimab-A Solid Tumor Program

Mar 25, 2025, 6:00 AM EDT - 4 months ago

Actinium Pharmaceuticals to Host KOL Investor Call at 8am ET Today to Highlight Revamped Clinical Programs and Expanded Market Opportunities Including Newly Initiated Actimab-A Solid Tumor Program

Actinium Pharmaceuticals Announces Supply Agreement with Eckert & Ziegler for Ac-225 Radioisotope to Support Comprehensive Development Activities

Mar 24, 2025, 4:15 PM EDT - 4 months ago

Actinium Pharmaceuticals Announces Supply Agreement with Eckert & Ziegler for Ac-225 Radioisotope to Support Comprehensive Development Activities

Actinium Pharmaceuticals Announces Research Collaboration with Memorial Sloan Kettering to Support Further Clinical Expansion of Actimab-A's Backbone Therapy Strategy

Mar 20, 2025, 8:00 AM EDT - 4 months ago

Actinium Pharmaceuticals Announces Research Collaboration with Memorial Sloan Kettering to Support Further Clinical Expansion of Actimab-A's Backbone Therapy Strategy

Actinium Pharmaceuticals to Host Investor KOL Call with Dr. Ehab Atallah of the Medical College of Wisconsin and Provide a Pipeline Update Highlighting Revamped Clinical Programs and Expanded Market Opportunities for Actimab-A and Iomab-ACT with Clinical Data in 2H:2025

Mar 19, 2025, 8:30 AM EDT - 4 months ago

Actinium Pharmaceuticals to Host Investor KOL Call with Dr. Ehab Atallah of the Medical College of Wisconsin and Provide a Pipeline Update Highlighting Revamped Clinical Programs and Expanded Market Opportunities for Actimab-A and Iomab-ACT with Clinical Data in 2H:2025

gooddoggie
gooddoggie Aug. 1 at 6:38 PM
$ATNM Ask Ann, August 1, 2025 Dear Ann, when I have severed heads they get so hot out in the sun. What can I do? -Muffy from Memphis Dear Muffy, I usually keep umbrellas just for that purpose. Also you might try severing the heads in cooler months. -Ann
0 · Reply
Raxothus
Raxothus Aug. 1 at 5:31 PM
EOD FOLLOW-UP - 08/01/25 Tracking continuation watch from 07/31 based on today’s highs vs prior close ✅ $AVTX – Closed 7.89, hit 8.75 (+10.9%). Strong open pop, but failed to hold VWAP or push further. ✅ $FRGE – Closed 21.90, hit 23.37 (+6.7%). Strong breakout at open, clean continuation. ❌ $ATNM – Closed 1.66, hit 1.68 (+1.2%). Weak range, lacked momentum. ❌ $ENGN – Closed 3.77, hit 3.86 (+2.4%). Modest move, but reclaimed VWAP and showed decent structure. ❌ $CCRD – Closed 29.00, hit 28.17 (–2.9%). Gapped down and faded. No continuation. 📊 Recap Total: 5 Winners: 2 Faders: 3 Accuracy: 40% ⚠️ $FRGE gave a clean continuation. $AVTX technically hit +10%, but failed to hold structure or VWAP. $ATNM, $ENGN and $CCRD failed to deliver range or setup. #VWAP #Continuation #SmallCaps #DayTrading #EODSetups #Accountability
0 · Reply
johnny4cures
johnny4cures Aug. 1 at 5:20 PM
$ATNM new data I believe
0 · Reply
gooddoggie
gooddoggie Aug. 1 at 4:49 PM
$ATNM Why I hate Mondays.
1 · Reply
gooddoggie
gooddoggie Aug. 1 at 10:12 AM
$ATNM UhOh. Now we’ve done it.
1 · Reply
johnny4cures
johnny4cures Aug. 1 at 3:59 AM
$ATNM an old publication but goodie
0 · Reply
johnny4cures
johnny4cures Aug. 1 at 3:41 AM
$ATNM If it is so obvious, the therapy works better than soc, fast track breakthroughs will speed up in the future, breakneck speed on approvals with ai, right.
1 · Reply
Raxothus
Raxothus Jul. 31 at 7:30 PM
EOD CONTINUATION WATCHLIST – 07/31/25 Focused on stocks that held VWAP and pushed into Power Hour with strength. $AVTX – 19.07% move, 4.7x volume, 9.1% VWAP stretch. Micro float. Strong move and held well above VWAP into close. Needs open over 7.96+ for continuation $FRGE – 26.4% move, 3.0x volume, 6.9% VWAP stretch. Micro float. Explosive action with strong close. Watching for gap and clean open over 21.8+ to extend $ATNM – 7.01% move, 2.0x volume, 3.0% VWAP stretch. Small float. Grinded up steadily with VWAP support. Needs push over 1.74 to stay in play $ENGN – 5.71% move, 6.2x volume, -0.5% VWAP stretch. Small float. Volume was strong, but faded late. Needs VWAP reclaim over 3.80+ to reset momentum $CCRD – 10.55% move, 6.1x volume, -0.5% VWAP stretch. Micro float. Volume surged but no late power. Needs strong gap and reclaim over 29.76+ to watch Watching for gap and VWAP continuation only. Catalyst + volume = edge. No random holds. #EOD #VWAP #Momentum #SmallCaps #DayTrading #ContinuationSetups
0 · Reply
noggindog
noggindog Jul. 31 at 5:05 PM
$ATNM Up 1% today AND volume above normal. Could this be a start to going above $2?
0 · Reply
johnny4cures
johnny4cures Jul. 31 at 4:45 PM
$ATNM How about some contrast and color on the potential for ATNM-400. Sales between the makers of keytuda and opdivo ~40 billion x 3 years from now is =120 billion with LOE on the horizon. Sales between pluvicto and Xtandi ~7 billion × 3 years =21 billion. Can they afford not to buy Actinium is a good question?
1 · Reply
excobito
excobito Jul. 31 at 4:29 PM
$ATNM I think I've finally lost the faith here... It looks like all the major holders are backing off. The science always looks great in PRs, but I'm doubtful it's ever going to actually materialize into something sellable... so, I think I'm just going to ride the (frequent) waves of manipulation, and hopefully recoup some of the loss.
2 · Reply
janlukas
janlukas Jul. 31 at 4:18 PM
$ATNM How much could this company potentially be worth? I think it's a lot, and I say this rationally, because even if it's far from commercial, it could be a drug that conquers one of the most common cancers. Big pharma certainly won't allow this; it will be acquired first. But how much do you think it's potentially worth?
1 · Reply
janlukas
janlukas Jul. 31 at 4:18 PM
$ATNM
0 · Reply
johnny4cures
johnny4cures Jul. 31 at 4:14 PM
$ATNM New chart, ATNM-400 keeps adding to the durability(longer life expectancy)for the response to Pca.
0 · Reply
johnny4cures
johnny4cures Jul. 31 at 4:08 PM
$ATNM "Targeted radiotherapy is a growing field in prostate cancer, dominated by PSMA-targeting agents like Pluvicto®, which had sales of over $1.3 billion in 2024, yet many patients either lack PSMA expression or develop resistance to Pluvicto®. In the U.S., 40,000–60,000 mCRPC patients annually progress after ARPIs such as Xtandi®, which had sales of over $5.9 billion in 2024, highlighting a significant unmet need." This final statement is for clarification on where this may be headed, ATNM-400!
0 · Reply
johnny4cures
johnny4cures Jul. 31 at 4:06 PM
$ATNM Astellas and Pfizer market Xtandi for prostate cancer, which this new data from Actinium and ATNM-400 is showing marked improvements in treating Pca.
1 · Reply
yellowjacker
yellowjacker Jul. 31 at 4:03 PM
$ATNM This is so off the radar screen. Bought at $1.55 before the opening. People after the news still not see it. Just wait until they figure it out.
0 · Reply
johnny4cures
johnny4cures Jul. 31 at 3:58 PM
$ATNM This is new
1 · Reply
johnny4cures
johnny4cures Jul. 31 at 3:48 PM
$ATNM Having 4 multi-billion potent pipeline candidates will only improve the odds of BO.
0 · Reply
johnny4cures
johnny4cures Jul. 31 at 3:44 PM
$ATNM -400 is transformative!
0 · Reply
gooddoggie
gooddoggie Jul. 31 at 3:44 PM
$ATNM Seth: “I’m very excited to announce that we will have final Phase 3 data on ATNM-400 in H2 2037. During the Phase 2 trial we will begin allowing cross-overs to be treated.”
0 · Reply
johnny4cures
johnny4cures Jul. 31 at 3:43 PM
$ATNM One major issue is what the FDA is, the OS, which this drug is smashing successfully, the survival endpoint, and this is what they want to see for approval.
0 · Reply